• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $WGS

    GeneDx Holdings Corp.

    Subscribe to $WGS
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    IPO Year: 2020

    Exchange: NASDAQ

    Recent Analyst Ratings for GeneDx Holdings Corp.

    DatePrice TargetRatingAnalyst
    8/28/2024$34.00Equal Weight
    Wells Fargo
    7/10/2024$43.00Buy
    Craig Hallum
    6/3/2024$21.00Hold
    Jefferies
    See more ratings

    GeneDx Holdings Corp. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GeneDx Announces Completion of Fabric Genomics Acquisition

      Closing unlocks the next phase of genomic medicine, enabling an end-to-end centralized and decentralized model for offering clinically-actionable genomic insights at a global scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretation. Together, GeneDx and Fabric Genomics are ushering in the next era of genomic medicine, enabling decentralized testing powered by centralized intelligence to set the standard of care across the globe. "Healthcare is at an inflection point where genomic insights must be integrated into standar

      5/7/25 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

      Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue Generated first quarter 2025 adjusted net income1 of $7.7 million Announced plans to acquire Fabric Genomics Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025 GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025. "Healthcare is at an inflection point where integrating genomic ins

      4/30/25 6:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale

      Combining GeneDx's industry-leading rare disease data asset and Fabric Genomics' AI-powered platform furthers the Company's leadership and creates an unrivaled platform to deliver global access to genomic information Accelerates the NICU, enables newborn screening, and opens global market opportunities with on-site sequencing and decentralized interpretation GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation. The transaction enables GeneDx's leadership in the next phase of genomic medicine: decentralized testing with centralized intelligence. "H

      4/16/25 6:00:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

      GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2025 before the market opens on Wednesday, April 30, 2025. Management will host a conference call that day to discuss first quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone de

      4/8/25 8:05:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

      Focus on Inborn Errors of Immunity expands access to exome and genome testing for the known 200,000+ patients in the US 1 impacted by these conditions and opens new opportunities for GeneDx and biopharma partners to accelerate the path to treatment for patients GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the commercial expansion into Inborn Errors of Immunity (IEI), a group of nearly 500 genetic disorders that impair immune function2, increasing susceptibility to infections, autoimmunity, and inflammatory conditions. The strategic expansion reinforces GeneDx's mission to improve patient outcomes by providing exome and genom

      4/3/25 8:00:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of March 15, 2025, the compensation committee of GeneDx's board of directors granted 46,340 restricted stock units ("RSUs") to ten newly-hired employees as inducements material to each employee entering into employment with GeneDx. The RSUs were granted under GeneDx's 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in equal annual installments over a four-year period, subject to the employee's continued service with GeneDx on each applicable vesting date. Each RSU represents a contingent right to receive 1 sh

      3/20/25 4:05:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

      GeneDx recognized for its innovative approach to accelerating genetic diagnosis and transforming the future of healthcare by ending the diagnostic odyssey GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, announced today they have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025, and recognized as the No. 2 in the Biotech category. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy. "Since its inception 25 years ago, GeneDx has been the pioneer in bringi

      3/18/25 7:05:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

      GeneDx's Multiscore tool to be showcased at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining workflows, and enhancing clinical insights. Multiscore is embedded into GeneDx's interpretation platform as a decision support tool to help clinical geneticists focus on the most relevant genes during their clinical analysis. GeneDx will present the AI-powered decision support tool at ACMG, in a session: Multiscore,

      3/13/25 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting

      Presentations to highlight how GeneDx is leveraging AI to drive both better patient care and scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, announced today its scientific contributions will be presented at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. GeneDx will showcase its leadership in genomic research and innovation, driving the industry forward with three platform presentations and two poster presentations. GeneDx earned one of the limited spots available for an industry-specific platform presentation on its AI-powered gene ranker embedded in its interpretation platform to enh

      3/13/25 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication

      GeneDx Recognizes Cerebral Palsy Awareness Month with Commitment to Improve Access to Testing GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, announced today an indication expansion for its industry leading genetic testing to now include cerebral palsy (CP). In conjunction with Cerebral Palsy Awareness Month, the company is expanding its strategy of focusing on pediatric rare disease patients to now include offering testing for pediatric patients with CP. This strategic indication expansion underscores the importance of improving access to exome and genome testing for patients with CP to shorten the diagnostic odyssey and accelerate the path t

      3/4/25 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    GeneDx Holdings Corp. SEC Filings

    See more
    • SEC Form DEFA14A filed by GeneDx Holdings Corp.

      DEFA14A - GeneDx Holdings Corp. (0001818331) (Filer)

      4/30/25 4:34:16 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form DEF 14A filed by GeneDx Holdings Corp.

      DEF 14A - GeneDx Holdings Corp. (0001818331) (Filer)

      4/30/25 4:33:10 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 10-Q filed by GeneDx Holdings Corp.

      10-Q - GeneDx Holdings Corp. (0001818331) (Filer)

      4/30/25 7:04:19 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GeneDx Holdings Corp. (0001818331) (Filer)

      4/30/25 7:02:36 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 144 filed by GeneDx Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      4/29/25 9:51:50 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Holdings Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GeneDx Holdings Corp. (0001818331) (Filer)

      4/16/25 7:01:13 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 144 filed by GeneDx Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      4/9/25 5:10:23 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 144 filed by GeneDx Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      3/26/25 6:34:21 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 144 filed by GeneDx Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      3/17/25 6:44:11 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 144 filed by GeneDx Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      3/13/25 7:03:42 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    GeneDx Holdings Corp. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on GeneDx with a new price target

      Wells Fargo initiated coverage of GeneDx with a rating of Equal Weight and set a new price target of $34.00

      8/28/24 7:58:09 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Craig Hallum initiated coverage on GeneDx with a new price target

      Craig Hallum initiated coverage of GeneDx with a rating of Buy and set a new price target of $43.00

      7/10/24 8:09:23 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Jefferies resumed coverage on GeneDx with a new price target

      Jefferies resumed coverage of GeneDx with a rating of Hold and set a new price target of $21.00

      6/3/24 8:54:48 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    GeneDx Holdings Corp. Leadership Updates

    Live Leadership Updates

    See more
    • GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

      Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More New Executive Leadership Positions Company for Growth and Scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team. As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program

      1/2/25 4:01:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

      Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.

      11/18/24 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Anagenex Strengthens Board of Directors with Appointments of Robert Forrester and Isaac Ro

      Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines, today announced the appointment of Robert Forrester as Executive Chairman of its Board of Directors. The company also welcomed Isaac Ro to its Board of Directors. "Robert and Isaac's extensive experience as life science executives is invaluable to the Anagenex team as we realize our vision of becoming a vertically integrated small molecule drug discovery company," said Nicolas Tilmans, CEO of Anagenex. "Our unique AI driven platform has already powered two lead programs with novel chemical matter and co

      11/16/23 8:00:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Announces Evolution of Executive Leadership Team

      STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- GeneDx (NASDAQ:WGS) a leader in delivering improved health outcomes through genomic and clinical insights, today announced the expansion and evolution of its executive leadership team with the appointment of Melanie Duquette as Chief Growth Officer and Jennifer (Jen) Brendel as Chief of Corporate Affairs. Both executives will report to Katherine Stueland, CEO and President, and will collaborate in continuing to strengthen GeneDx's market leading position in genomic interpretation and health insights. Bringing nearly 20 years of genomic industry experience, in her role as Chief Growth Officer, Melanie will be responsible for the company's

      9/11/23 8:00:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel

      STAMFORD, Conn., April 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Devin K. Schaffer has been appointed General Counsel, effective April 24, 2023. As a member of the executive leadership team, Devin will report directly to Katherine Stueland, President and CEO, and will be responsible for all legal, compliance, and regulatory activities for GeneDx. "We're so happy to have Devin join the team. He is a deeply experienced healthcare legal executive and a natural leader, with a proven track record of bringing people together to solve complex problems in a patient-centric way," s

      4/3/23 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    GeneDx Holdings Corp. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Meister Keith A. was granted 434,848 shares (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/6/25 9:45:05 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Director Pfenniger Richard C Jr converted options into 918 shares, increasing direct ownership by 3% to 28,582 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/5/25 4:48:43 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 753 shares, sold $43,879 worth of shares (388 units at $113.09) and was granted 420 shares, increasing direct ownership by 26% to 3,757 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/1/25 7:46:17 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Chief Executive Officer Stueland Katherine converted options into 3,874 shares and sold $243,596 worth of shares (2,154 units at $113.09), increasing direct ownership by 100% to 3,440 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/1/25 7:44:43 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • CHIEF FINANCIAL OFFICER Feeley Kevin exercised 1,246 shares at a strike of $32.67 and sold $1,430,334 worth of shares (15,516 units at $92.18), decreasing direct ownership by 89% to 1,726 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      4/10/25 4:12:22 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Chief Executive Officer Stueland Katherine sold $4,175,817 worth of shares (46,594 units at $89.62), decreasing direct ownership by 96% to 1,720 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      4/10/25 4:11:47 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • CHIEF FINANCIAL OFFICER Feeley Kevin sold $836,211 worth of shares (8,746 units at $95.61) and converted options into 16,250 shares, increasing direct ownership by 88% to 15,996 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      3/28/25 4:07:59 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Chief Executive Officer Stueland Katherine sold $4,451,084 worth of shares (46,551 units at $95.62) and converted options into 80,000 shares, increasing direct ownership by 225% to 48,314 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      3/28/25 4:07:12 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Chief Executive Officer Stueland Katherine sold $1,117,566 worth of shares (11,637 units at $96.04) and converted options into 18,750 shares, increasing direct ownership by 92% to 14,865 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      3/17/25 9:51:08 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • CHIEF FINANCIAL OFFICER Feeley Kevin sold $398,767 worth of shares (4,151 units at $96.07), increasing direct ownership by 56% to 8,492 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      3/17/25 9:50:37 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    GeneDx Holdings Corp. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/20/24 9:36:13 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/19/24 8:00:24 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/8/24 5:23:34 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13G/A filed by GeneDx Holdings Corp.

      SC 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/8/24 11:06:51 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/4/24 5:00:35 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      9/18/24 4:13:05 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      8/23/24 5:33:46 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      8/12/24 6:27:05 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      7/26/24 7:43:51 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      7/5/24 4:14:38 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    GeneDx Holdings Corp. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Casdin Capital, Llc bought $2,757,117 worth of shares (130,000 units at $21.21) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      6/5/24 8:45:06 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Casdin Capital, Llc bought $842,604 worth of shares (40,000 units at $21.07) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/31/24 5:37:30 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Casdin Capital, Llc bought $3,424,989 worth of shares (170,000 units at $20.15) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/28/24 8:40:42 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Casdin Capital, Llc bought $1,165,295 worth of shares (50,000 units at $23.31) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/15/24 6:16:34 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Casdin Capital, Llc bought $357,652 worth of shares (40,900 units at $8.74) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      3/6/24 7:32:09 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    GeneDx Holdings Corp. Financials

    Live finance-specific insights

    See more
    • GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

      Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue Generated first quarter 2025 adjusted net income1 of $7.7 million Announced plans to acquire Fabric Genomics Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025 GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025. "Healthcare is at an inflection point where integrating genomic ins

      4/30/25 6:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

      GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2025 before the market opens on Wednesday, April 30, 2025. Management will host a conference call that day to discuss first quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone de

      4/8/25 8:05:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025

      GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, announced it will release financial results for the fourth quarter 2024 and the full year 2024 before the market opens on Tuesday, February 18, 2025. Management will host a conference call that day to discuss fourth quarter 2024 and full year 2024 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (

      1/28/25 4:30:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Announces Preliminary 2024 Financial Results

      Expects to exceed guidance with full year 2024 revenues1 of at least $299 million Expects fourth quarter 2024 revenues1 of at least $92 million Expects to exceed guidance with full year 2024 adjusted gross margin1 of at least 64% Expects fourth quarter 2024 adjusted gross margin1 of at least 68% GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2024. "2024 was a transformative year for GeneDx, as we achieved our profitability milestone of adjusted net income, released landmark studies, strengthened our products and expanded our team to se

      1/13/25 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

      Achieved profitability milestone with third quarter adjusted net income1 of $1.2M Reported third quarter 2024 revenues2 of $76.6M with 77% year-over-year growth of exome and genome test revenue Expanded third quarter 2024 adjusted gross margins2 to 64% Raising guidance to deliver between $284M and $290M in FY 2024 revenue GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2024. "We delivered 77% growth on exome and genome revenues in Q3 and have reached the point of profitability, a significant milestone in our co

      10/29/24 8:00:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

      GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024. Management will host a conference call that day to discuss third quarter 2024 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone de

      10/3/24 4:05:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights

      Reported second quarter 2024 revenue from continuing operations1 of $68.9M with 77% year-over-year growth of exome and genome test revenue Expanded second quarter 2024 adjusted gross margins2 from continuing operations to 62% Narrowed second quarter 2024 adjusted net loss2 to $2.7M Raising guidance to deliver between $255M and $265M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2024. "Our continued organizational focus on execution fueled o

      7/30/24 4:05:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024

      STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024. Management will host a conference call that day to discuss second quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.  Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/.  About GeneDx 

      7/11/24 4:05:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports First Quarter 2024 Financial Results and Business Highlights

      Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins2 from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss2 to $8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMFORD, Conn., April 29, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its f

      4/29/24 4:05:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology